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Abstract 
Objectives: Anti-ganglioside antibodies are present in about half of the patients with 
Guillain-Barré syndrome (GBS). Recently it has been shown that a considerable proportion of 
these patients has serum antibodies against antigenic epitopes formed by a complex of two 
different gangliosides. However, direct experimental evidence for neuropathogenicity of this 
special category of antibodies is currently lacking. Here we explored a series of GBS and 
GBS-variant sera with anti-ganglioside-complex antibodies for their ability to induce 
complement-dependent deleterious effects at the living neuronal membrane. 
Methods: The neuropathophysiological potential of 31 GBS sera containing either anti-
GM1/GD1a- or anti-GM1/GQ1b-ganglioside-complex antibodies was studied at motor nerve 
terminal presynaptic membranes in the mouse phrenic nerve/diaphragm muscle ex vivo 
experimental model. With electrophysiological measurements and confocal fluorescence 
microscopy we assessed and quantified the damaging effect on neuronal membranes by anti-
ganglioside-complex antibodies. 
Results: We show that anti-GM1/GD1a- and anti-GM1/GQ1b-ganglioside-complex positive 
sera can induce complement-mediated functional and morphological injury at mouse motor 
nerve terminals ex vivo. Of the 31 investigated anti-ganglioside-complex patient sera, 17 sera 
induced increases in miniature endplate potential frequency in this experimental model, 
mostly associated with muscle fibre twitches. Variability in potency was observed, with the 
anti-GM1/GD1a-complex sera inducing the most outspoken effects. 
Conclusions: This study demonstrates the presence of ganglioside-complexes as available 
antigens in living neuronal membranes and supplies proof-of-principle that anti-ganglioside-
complex antibodies in sera from GBS patients can induce complement-mediated damage. 
This strongly supports the hypothesis that autoimmune targeting of ganglioside-complexes is 
of pathogenic relevance in a proportion of GBS patients. 
 
 
Keywords: antibody, ganglioside, Guillain-Barré syndrome, neuromuscular junction, 
pathophysiology  
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Introduction 
Gangliosides form a family of sialic acid-containing amphiphilic glycosphingolipids that are 
enriched in neuronal membranes. Anti-ganglioside antibodies can be detected in around 50% 
of patients suffering from Guillain-Barré syndrome (GBS) or clinical variants, which are 
postinfectious peripheral neuropathies with diverse motor and sensory disturbances.1-3 Anti-
ganglioside antibodies are thought to exert neuropathogenic effects, either directly or through 
complement activation, on peripheral nerve axons including motor nerve terminals.3-5  
It has been recently recognized that combinations of two different gangliosides can form a 
novel antigenic glycoepitope and that some GBS patients have antibodies against such a 
complex.1,6,7 Clinical correlation and fine-specificity studies estimate that 10-20% of GBS 
patients has anti-ganglioside-complex antibodies.2,8,9 Interestingly, GBS patients with anti-
ganglioside-complex antibodies seem to have more severe disease symptoms than patients 
with antibodies against single gangliosides. In particular GBS patients (from a Japanese 
population) with antibodies directed against GD1a/GD1b- and GD1b/GT1b-complexes more 
often require mechanical ventilation.8 However, this was not confirmed by others in an Italian 
GBS patient cohort.2 In the GBS variant Miller Fisher syndrome (MFS), associated with anti-
GQ1b ganglioside antibodies and characterized by ophthalmoplegia, ataxia and areflexia, the 
incidence of anti-complex antibodies seems higher than in GBS. One study showed that 7 of 
the 12 investigated MFS sera contained antibodies against a complex of at least GQ1b or 
GT1a and another ganglioside.10 
The observations that anti-ganglioside-complex antibodies disappear upon clinical 
recovery,9 as occurs with antibodies against single gangliosides, in combination with their 
association with particular disease phenotypes suggests that they play a neuropathogenic role. 
However, this has not yet been directly shown in experiments on living neuronal membrane. 
Previously, we have demonstrated that antibodies against single gangliosides can induce 
complement-mediated damage at neuronal membranes of motor axon terminals in mouse 
neuromuscular junctions (NMJs), reviewed in.4 This effect is electrophysiologically 
hallmarked by a temporary extremely high frequency of miniature endplate potentials 
(MEPPs, the postsynaptic responses to uniquantal acetylcholine release), causing 
asynchronous muscle fiber twitches and, eventually, depletion of neurotransmitter which 
results in transmission block and thus paralyzes the muscle. Here we explored a first series of 
21 GBS sera with anti-GM1/GD1a-complex antibodies and 10 GBS variant sera with anti-
GM1/GQ1b-complex antibodies for their ability to induce complement-dependent deleterious 
effects in the mouse NMJ model system.
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Methods 
Patient sera and mouse monoclonal antibodies 
Acute-phase serum from 31 GBS (variant) patients from Japan (26 sera), The Netherlands (4 
sera) and Bangladesh (1 serum), were obtained with informed consent and local Medical 
Ethical Committee approval and stored until experimental use at -80C. Normal human serum 
(NHS) from a healthy donor, stored in 0.5 ml aliquots at -80 C, was used as complement 
source. Mouse monoclonal antibodies (mAbs) against GQ1b (CGM3; 50 μg/ml), GD1a 
(MOG35; 100 μg/ml) and GM1 (DG2; 100 μg/ml) were used as positive controls.4,11-13 Patient 
sera were complement-inactivated by heating at 56C for 30 min. Sera and mAbs were 
dialyzed (using a 10 kD molecular weight cut-off dialysis membrane) overnight at 4C 
against Ringer’s solution (116 mM NaCl, 4.5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 1 mM 
NaH2PO4, 23 mM NaHCO3, 11 mM glucose, pH 7.4), pre-gassed with 95%-O2 / 5%-CO2.  
 
Enzyme-linked immunosorbent assay  
Sera were tested in ELISA as described 9 for IgM and IgG antibody activity against individual 
gangliosides and complexes, as indicated in the Results. Serum (1:100) scoring an optical 
density (OD) of >0.2 was considered positive. For anti-ganglioside-complex antibodies, 
positivity in sera was defined as having an OD of >0.2 higher than the highest OD for 
antibodies against the two individual gangliosides.9,14 All samples were tested in duplicate. 
Positive sera were titrated using two-fold serial dilution series starting at 1:100. The 
reciprocal of the highest dilution that resulted in an OD higher than the cut-off value (0.2) was 
taken to be the titer. 
 
Bioassays on mouse hemidiaphragm-phrenic nerve preparations 
Male and female wild-type and GD3-synthase knockout (GD3s-KO) mice 15 were used at 1-
4.5 months of age. GD3s-KO mice lack the b- and c-series gangliosides due to genetic 
absence of GD3-synthase (Fig. 1).16 Mice were killed with CO2 and hemidiaphragms with 
phrenic nerves were dissected and kept in Ringer's medium at room temperature (20-22C). 
Muscles were incubated with heat-inactivated (30 min at 56C to destroy complement) GBS 
serum diluted at 33% in Ringer's medium or mouse mAbs dissolved in Ringer's for 3 h at 
32ºC, rinsed in Ringer's for 10 min and exposed to 33% NHS in Ringer's for 1 h at room 
temperature. Micro-electrode recording of MEPPs (10-30 NMJs per session) and visual 
scoring of spontaneous asynchronous fiber twitching (0 for no twitching across the 
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hemidiaphragm, 1 for twitching of <10 fibers, 2 for a small amount, 3 for a moderate amount 
and 4 for an extensive amount) were done as described.15,17 Depending on the available 
volumes, sera were tested 1-4 times and the mean values of the parameters were calculated. 
Animal experiments were carried out according to Dutch law and Leiden University 
guidelines, including approval of the Experimental Animal Committee of the Leiden 
University Medical Center.  
 
Complement immunohistochemistry 
C3c deposition at NMJs was quantified in a selection of the electrophysiologically tested 
samples, as described previously.11 IgG and membrane attack complex deposition at NMJs as 
well as neurofilament presence at terminal motor nerve was qualitatively determined with 
confocal fluorescence microscopy, as described previously.11,17 
 
Statistical analysis 
The statistical significance of the correlation between the serum titer of antibodies against 
ganglioside-complexes, the mean MEPP frequency elevation a serum had induced at mouse 
NMJs and the C3c complement deposition values was tested for with the Spearman’s rank 
correlation test using the VassarStats Website for Statistical Computation 
(http://faculty.vassar.edu/lowry/VassarStats.html), with p-values <0.05 considered as 
statistically significant. 
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Results 
Anti-ganglioside-complex antibodies tests 
On the basis of the ELISA results, sera were classified into two categories (Table 1): 1) anti-
GM1/GD1a-complex positive (21 sera: #1-21) and 2) anti-GM1/GQ1b-complex positive (10 
sera: #22-31), as determined by the centre of origin. In view of the possible inter-laboratory 
variation in anti-ganglioside antibody assays, 18 all sera were re-tested in ELISA for IgG and 
IgM antibodies against gangliosides GM1, GQ1b, GD1a and GD1b and ganglioside 
complexes GM1/GQ1b, GM1/GD1a, GM1/GD1b, GD1a/GD1b. Anti-ganglioside-complex 
positivity was confirmed in all but two sera (#22 and #29), which were negative for anti-
GM1/GQ1b-complex. They were still included because they had been defined (low) positive 
when tested in Japan. Many sera (19/31) showed additional activity against one or both of the 
individual gangliosides of the complex, but generally these titers were only very low and 
always much lower than the titer of the anti-complex antibodies (Table 1). We reviewed the 
clinical neurophysiological data (mostly from arm muscle and nerve) from the patients whose 
serum was tested in the present study (Table 1). From 20 of the 21 anti-GM1/GD1a-complex 
positive patients data was available. The majority (15/20) had a reduced compound muscle 
action potential amplitude. Distal motor latency was normal in most patients (13/20) but was 
increased in 7 of the 20 patients. From 6 of the 10 anti-GM1/GQ1b-complex positive patients 
the neurophysiological data was available and was all normal, except for a reduced compound 
muscle action potential of patient #30. 
 
Pathophysiological effects at mouse NMJs 
The antigenic ganglioside density on neuronal membranes is an important factor in the 
pathogenicity of anti-ganglioside antibodies.12 To optimize our experimental model for anti-
GM1/GD1a-complex antibodies we used diaphragm muscles of GD3s-KO mice.16 These 
mice genetically lack GD3-synthase and are therefore unable to synthesize b- and c-series 
gangliosides (Fig. 1). There is direct biochemical proof that these mice upregulate the 
membrane density of a-series gangliosides GM1 and GD1a in the brain,16 and we have 
previously shown indirectly with electrophysiological and fluorescence microscopical 
methods using anti-GD1a and anti-GM1 mAbs that this is also the case at motor nerve 
terminal membrane at the NMJ.11,12 At GD3s-KO NMJs, 12 of the 21 anti-GM1/GD1a-
complex sera induced elevations of MEPP frequency (i.e. >2.4 /s, twice the control mean) 
during the NHS incubation (range 3.5-58.9 /s; pooled control mean before incubations was 
1.2 /s; Fig. 2A, Fig. 3A, Table 1). The elevated MEPP frequencies correlated positively and in 
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a statistically highly significant way with the titer of the anti-GM1/GD1a-complex antibodies 
(p<0.01, r=0.65, Spearman’s rank correlation test, Fig. 4). Such a positive correlation was not 
observed between elevated MEPP frequency and the titer of possible additionally present 
antibodies against single gangliosides GM1 (p=0.196, r=0.30) or GD1a (p=0.07, r=0.4). From 
10 of the 21 sera, sufficient serum was available to be also studied at wild-type NMJs: only 
two of those sera (#2 and #11) induced (moderate) elevation of MEPP frequency (to 4.6 and 
3.2 /s, respectively, Table 1). With 5 of the 10 anti-GM1/GQ1b-complex sera, moderately 
elevated MEPP frequencies were observed (range 3.3-7.2 /s) at wild-type NMJs, without 
correlation with anti-GM1/GQ1b-complex titer (p=0.74, r=0.12, Spearman’s rank correlation 
test). No effect of these sera was observed on MEPP frequency at GD3s-KO NMJs (Fig. 2A, 
Table 1), which was as expected because the neuronal membranes of these mutant mice lack 
ganglioside GQ1b (Fig. 1).  
The elevated MEPP frequency induced by anti-ganglioside-complex sera was generally 
accompanied by irregular twitching of individual muscle fibers throughout the preparation, 
(Fig. 2B, Table 1). Such twitches are most likely caused by superimposed MEPPs crossing 
the firing threshold of muscle fibers and have also been observed in our previous studies on 
the pathophysiological effects of sera positive for antibodies against single gangliosides and 
of mouse monoclonal antibodies against single gangsliosides.17,19 Mean twitching score was 
<0.5 in control (pre-incubation) sessions and was similarly low with anti-GM1/GD1a-
complex sera tested in wild-type muscle (range 0.0-0.6). In GD3s-KO muscles, 11 of these 21 
sera scored >1.0 (range 1.0-2.8, Fig. 2B). Seven of the 10 investigated anti-GM1/GQ1b-
complex sera scored >1.0 in wild-type muscles (range 1.2-2.3, Fig. 2B). At GD3s-KO 
muscles, two of these sera scored >1.0 (1.7 and 1.9). Mean positive control mAb score was 
>2.1, i.e. at GD3s-KO NMJs the anti-GM1 mAb DG2 scored 2.9 and the anti-GD1a mAb 
MOG35 scored 2.2, while at wild-type NMJs the anti-GQ1b mAb CGM3 scored 2.3.  
 
Complement deposition at the NMJ 
In our previous studies on antibodies against single gangliosides we have demonstrated that 
these can induce complement activation, culminating in membrane attack complex formation 
at the presynaptic nerve terminal and that this is underlying the observed temporary dramatic 
increase of MEPP frequency at the NMJ due to the excessive influx of Ca2+ through 
membrane attack complex pores in the presynaptic neuronal membrane.17,20,21 We 
investigated here with confocal fluorescence microscopy whether anti-ganglioside-complex 
antibody-containing sera also induced complement activation at the NMJ. For anti-
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GM1/GD1a-complex sera, complement C3c deposition at NMJs associated with elevated 
MEPP frequency (p<0.01, Spearman’s rank correlation test, Table 1, Fig. 3B). IgG and 
membrane attack complex deposition was observed at these NMJs, as well as neurofilament 
loss, indicating terminal motor axonal damage (Fig. 3B), as shown previously for antibodies 
against single gangliosides.22 For anti-GM1/GQ1b-complex sera, C3c deposition at NMJs was 
sparse and not consistently associated with MEPP frequency elevation (Table 1). 
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Discussion 
We here report that sera positive for either anti-GM1/GD1a-complex or anti-GM1/GQ1b-
complex antibodies clearly can produce pathophysiological effects at presynaptic neuronal 
membranes at NMJs in the mouse diaphragm/phrenic nerve ex vivo experimental model. 
Roughly half of the 31 anti-ganglioside-complex sera tested in the current experiments 
induced the effects, which were similar to those observed earlier with antibodies and sera with 
activity against either single gangliosides GQ1b, GD1a, GM1 or GD1b.4,11,12,21 In the set of 
21 anti-GM1/GD1a-complex positive sera, we found a statistically highly significant 
correlation between the MEPP frequency elevation observed in the electrophysiological 
experiments and the titer of this specific anti-complex antibody in the sera and, furthermore, 
an association with complement activation as quantified in fluorescence microscopical 
analyses. In previous studies using sera or antibodies against single gangliosides we showed 
that the utmost consequence at the mouse NMJ is block of evoked ACh release due to 
presynaptic focal complement-mediated lysis, leading to muscle paralysis. 4 Although we did 
not structurally monitor in the present studies whether or not anti-ganglioside complex sera 
induced these endpoint effects, some of them certainly caused (partial) block of the 
diaphragm muscle contraction evoked by nerve stimulation, as judged visually. However, 
especially with the sera that only induced moderate increases in MEPP frequency it is to be 
expected that they would not, or only after periods much longer than the current observation 
period of 1 h, lead to transmission block. 
Thus, we here for the first time demonstrate that anti-ganglioside-complex antibodies are 
capable of binding to living neuronal membranes and, by activating complement, can induce 
pathophysiological effects. These antibodies are therefore likely of pathogenic relevance, as 
also suggested from the clinical association with specific patterns of paralysis and, in some 
patient groups, mechanical ventilation.2,8 In a previous study, anti-GM1/GD1a-complex 
serum positivity was associated with a pure motor variant of GBS without severe cranial 
nerve involvement,9 suggesting a specific effect of these antibodies on motor axons. Our 
finding of deleterious effects of anti-ganglioside-complex antibodies at mouse motor nerve 
terminals suggests that these antibodies may, apart from causing motor axonal dysfunction, 
induce some degree of NMJ synaptopathy in GBS patients, potentially contributing to the 
paralytic symptoms. 
Due to the limited availability of most of the patient sera for repetitive experimental study 
and because of the heterogeneity of the anti-ganglioside(-complex) characteristics of the 
studied sera, some complexities of our results remain unresolved. First, not all sera induced 
 
  Zitman et al. 11
the deleterious effects at mouse NMJs. Second, some of the active sera, especially those from 
the anti-GM1/GQ1b-complex positive series, caused only moderate effects, i.e. the MEPP 
frequency remained lower than 10 /s, as compared to values of >20 MEPPs /s induced by the 
positive control mAbs and many of the active anti-GM1/GD1a-complex sera. These 
differences may relate to the titer and affinity variations of anti-ganglioside-complex 
antibodies amongst sera, together with the likely existence of an antibody binding threshold 
for the induction of pathophysiological effects at NMJs. Indeed, pathophysiological inactive 
or less active sera generally had low anti-ganglioside-complex titer and, at least in the anti-
GM1/GD1a-complex series, statistical analysis showed a clear correlation between the 
elevated MEPP frequency and antibody titer. Third, many active sera, especially the anti-
GM1/GD1a-complex positive ones, contained additional activities against single gangliosides 
GM1 and/or GD1a (Table 1), which in principle may have contributed to the effects. 
However, these single ganglioside antibody titers were generally (very) low, both in absolute 
sense as well as relative to the titers of the anti-GM1/GD1a-complex antibody in these sera. 
Furthermore there was no statistically significant correlation between the titer of anti-GM1 or 
anti-GD1a antibodies and the elevated MEPP frequency observed with the sera. Still, this co-
presence of anti-single-ganglioside antibodies complicates interpretation, in particular because 
four anti-GM1/GD1a-complex sera without additional activity against GM1 or GD1a lacked 
effects. This could be due to their only low-positive anti-GM1/GD1a-complex titers but this 
may also suggest that besides anti-GM1/GD1a-complex activity, some additional anti-
glycolipid or anti-glycolipid-complex activity is required for the neuropathophysiological 
effects. Any potential co-presence of anti-GQ1b single-ganglioside antibody in the anti-
GM1/GD1a-complex sera active at GD3s-KO NMJs could not have been of influence because 
GQ1b ganglioside is not expressed in the plasma membranes of GD3s-KO mice (Fig. 1). The 
strongest direct evidence for a neuropathophysiological effect of anti-GM1/GD1a-complex 
antibody came from the study of serum #5. The anti-GM1/GD1a-complex antibodies in this 
serum unambiguously were solely responsible for the complement-mediated 
neuropathophysiological effects at GD3s-KO NMJs because this serum contained no 
additional anti-GD1a or -GM1 single-ganglioside antibodies. Some activity against GD1b 
ganglioside and GD1b- and GQ1b-containing ganglioside complexes was detected in this 
serum (data not shown) but this was irrelevant because GD3s-KO tissue lacks the b-series 
gangliosides GD1b and GQ1b (Fig. 1). Thus, the results obtained with this particular serum 
clearly provide proof-of-principle that GBS anti-ganglioside-complex antibodies can induce 
neuropathophysiological effects at living neuronal membranes. 
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Activity against the single gangliosides GM1 or GQ1b was less of a confounding factor in 
the GM1/GQ1b-complex group where 7 of the 10 sera lacked single ganglioside antibodies. 
However, only three of those induced MEPP frequency elevations at wild-type NMJs and 
these effects were only rather modest in magnitude. In addition, complement deposition and 
muscle fibre twitching did not very well correlate with elevation of MEPP frequency. No 
statistically significant correlation was found between the anti-GM1/GQ1b-complex antibody 
titer of the sera in this series and the MEPP frequency that was observed at wild-type NMJs. 
This indicates that anti-GM1/GQ1b antibodies generally only induce relatively weak 
neuropathogenic effects in this experimental model.  
Anti-GM1/GD1a-complex sera induced either no neuropathophysiological effects or much 
less intense effects at wild-type NMJs, as compared to GD3s-KO NMJs. This indicates the 
requirement of an elevated anti-GM1/GD1a-complex antigen density for anti-GM1/GD1a-
complex antibodies to become neuropathogenic, because the a-series gangliosides GM1 and 
GD1a are upregulated in neuronal membranes of GD3s-KO mice, including motor nerve 
terminals.12,16 The ganglioside and ganglioside-complex expression pattern in different 
peripheral nerve membrane domains may vary considerably, both within and between species. 
It is even possible that certain GBS patients express particular predisposing ganglioside-
complex densities or configurations. Development of high-affinity mouse mAbs specific for 
ganglioside-complexes will be an essential next step, allowing more detailed experimental 
studies in which these issues can be explored. 
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Figure legends 
 
Figure 1. Ganglioside synthesis scheme  
Ganglioside nomenclature is according to Svennerholm.23 Membranes of wild-type mice 
contain all indicated gangliosides. GD3s-KO mice lack b- and c-series gangliosides (grey 
rectangle), due to absence of GD3-synthase. Cer = ceramide, GluCer = glucosylceramide, 
LacCer = lactosylceramide. 
 
Figure 2. Overview of the neuropathophysiological effects of the investigated anti-
ganglioside-complex sera 
(A) Effect of anti-ganglioside-complex sera on MEPP frequency at wild-type (left panel) and 
GD3s-KO (right panel) mouse diaphragm NMJs. Twelve of the 21 tested anti-GM1/GD1a-
complex sera induced MEPP frequency increases at GD3s-KO to a level of more than twice 
the pre-incubation control value (i.e. 2.4 /s, dashed line). Only two of the 10 anti-GM1/GD1a-
complex sera that could be tested at wild-type NMJs (modestly) increased MEPP frequency. 
Of the 10 investigated anti-GM1/GQ1b-complex sera, 5 induced (modest) MEPP frequency 
rise to levels of more than twice the control value, exclusively at wild-type NMJs. The anti-
GQ1b mAb CGM3 was used as a positive control in wild-type tissue; anti-GD1a mAb 
MOG35 and anti-GM1 mAb DG2 were used as positive controls in GD3s-KO tissue. (B) 
Effect of anti-ganglioside-complex sera on muscle fiber twitches at wild-type (left panel) and 
GD3s-KO (right panel) mouse NMJs. Most anti-ganglioside-complex sera that induced MEPP 
frequency elevation scored higher than 1 (dashed line) for muscle fiber twitching upon visual 
inspection. 
(Scoring: 0= no twitching, 1= twitching of <10 fibers, 2= a small amount, 3= a moderate 
amount and 4= an extensive amount of fibers) 
 
Figure 3. Examples of electrophysiological and morphological effects of anti-ganglioside-
complex sera on the mouse motor nerve terminal experimental model 
(A) Examples of MEPPs recorded at a GD3s-KO mouse diaphragm NMJs before incubation 
with complement-inactivated anti-GM1/GD1a-complex serum #8 (upper trace) and during 
subsequent incubation of the serum pre-incubated muscle with normal human serum as 
complement source (lower trace). Sweep length is 10 s. (B) Examples of C3c, membrane-
attack complex (MAC), IgG and neurofilament immunostaining at diaphragm NMJs 
(delineated by fluorescently labeled -bungarotoxin binding to acetylcholine receptors, left 
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column panels). Muscle preparations had been exposed to complement-inactivated anti-
GM1/GD1a-complex serum #2 (first row), serum #5 (second and third row) or complement-
inactivated normal human serum (as negative control, fourth row) and were all subsequently 
exposed to normal human serum as complement source. IgG and C3c deposition and 
associated neurofilament loss are shown at anti-GM1/GD1a-complex sera-treated NMJs. 
 
Figure 4. Positive correlation between anti-GM1/GD1a-complex titer of sera and the 
MEPP frequency induced at mouse NMJs 
Plot graph of the average MEPP frequency at NMJs of diaphragm muscles from GD3s-KO 
mice induced by anti-GM1/GD1a-complex-positive GBS sera against the titer of the anti-
GM1/GD1a-complex antibodies. Spearman’s rank correlation test showed a highly significant 
positive correlation (r=0.65, p<0.01).
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GD3s-KO mouse tissue wild-type mouse tissue patient 
neurophysiology pathophysiology pathophysiology  serum# 
CMAP DML 
anti-ganglioside titer 
fMEPP (/s) twitching 
C3c 
staining fMEPP (/s) twitching 
C3c 
staining 
anti-GM1/GD1a-complex sera    GM1/GD1a complex GM1 GD1a       
 1 = = G-25600 G-800 G-6400 58.9 + ++ 1.6 - - 
 2  = G-12800 G-400 G-1600 49.3 ++ + 3.2 - - 
 3  = G-51200 G-400 G-800 45.0 ++ + nt nt nt 
 4  = G-12800 G-400 G-400 36.8 ++ +++ 0.5 - nt 
 5   G-6400 - - 28.8 ++ ++ nt nt nt 
 6 = = G-6400 - G-100 27.0 ++ +++ 0.6 - nt 
 7  = G-12800 G-1600 G-100 19.8 ++ +++ 0.7 - nt 
 8   G-12800 G-1600 G-100 16.2 ++ ++ nt nt nt 
 9   G-6400 G-100 G-100 14.2 ++ ++ nt nt nt 
 10   G-6400 G-100 - 6.6 - nt 1.7 - + 
 11   G-12800 - G-200 4.9 + nt 4.6 - ++ 
 12   G-400 M-200 - 3.5 - nt nt nt nt 
 13 =  G-6400 G-100 - 2.1 - nt 0.5 - nt 
 14 nd nd G-200 - - 2.0 - + nt nt nt 
 15   G-400 - - 1.7 - + nt nt nt 
 16  = G-6400 - - 1.6 - nt nt nt nt 
 17 = = G-400 - - 1.4 + nt nt nt nt 
 18 = = G-3200 G-200 - 1.3 - + nt nt nt 
 19  = G-12800 G-100 G-800 1.1 - nt 1.5 - +++ 
 20   G-1600 G-200 G-100 1.1 - nt 2.0 - nt 
 21  = G-3200 G-800 G-400 1.1 - - nt nt nt 
anti-GM1/GQ1b-complex sera    GM1/GQ1b complex GM1 GQ1b       
 22 = = - † - - 1.6 - + 7.2 - + 
 23 = = G-1600 - G-400 1.8 - + 6.0 + ++ 
 24 nd nd G-800 - - 1.4 - + 4.6 ++ + 
 25 nd nd G-800 - - 2.1 + nt 4.3 + nt 
 26 nd nd G-3200 - G-400 1.5 - nt 3.3 + nt 
 27 = = G-1600 - - 1.9 - nt 2.3 + nt 
 28 nd nd G-400 - - 2.3 - nt 2.3 - nt 
 29 = = - † M-100 - 1.3 + nt 1.7 - nt 
 30  = G-400 - - 1.7 - nt 1.6 + nt 
 31 = = G-800 - - 1.2 - nt 1.6 + nt 
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Table 1. Patient neurophysiology, serum anti-ganglioside characteristics and 
neuropathogenicity of the investigated sera. 
Patient neurophysiology, serum anti-ganglioside antibody activity (either IgG (G) or IgM 
(M)), effects on MEPP frequency (fMEPP), muscle fiber twitching and C3c deposition at 
neuromuscular junctions of sera positive for either anti-GM1/GD1a antibodies (sera #1-21) or 
anti-GM1/GQ1b antibodies (sera #22-31). The sera have been ranked in descending order 
according to the observed MEPP frequency (for anti-GM1/GD1a-complex sera in GD3s-KO 
tissue and for anti-GM1/GQ1b-complex sera in wild-type tissue). 
 
Anti-ganglioside titer: - = negative 
 
Twitching: - = <1.0; + = between 1.0 and 2.0; ++ = >2.0. 
 
C3c staining was performed in two comparable runs on 17 and 7 tissue samples. Indicated is 
the relative intensity within these series: + = low; ++ = moderate; +++ = high. 
 
† these sera were tested positive for anti-GM1/GQ1b-complex in the centre of origin 
 
CMAP = compound muscle action potential 
DML = distal motor latency 
nt = not tested 
nd = no data available 
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